Regimen 2026 Peptide Tracking Report
Published May 2026. This is the first annual aggregate report on how Regimen users are actually tracking their peptide, TRT, and GLP-1 protocols. All numbers below are drawn from active compound protocols on the platform, anonymized and aggregated. We will update these figures quarterly.
Regimen is a tracking and logging tool used by people running peptide, GLP-1, and TRT protocols. Until now, the public conversation about how these protocols are actually structured has been driven by anecdote, forum threads, and influencer content. This report is the first time we are publishing aggregate data from active users to add a real-world reference point.
Methodology
Numbers below are computed from active compound protocols logged in Regimen as of May 2026. An "active compound protocol" is any compound a user has logged a dose for in the trailing 30 days. We exclude paused protocols, deleted protocols, and protocols flagged as historical reference.
Totals are computed across all users, anonymized, and reported in aggregate. No individual user data, identifying information, or geographic precision finer than country is used. Percentages are rounded to the nearest whole number and may not sum to exactly 100 due to rounding.
The pain-point figure referenced below is from a separate 2025 in-app Regimen user survey, not from protocol logs.
Dosing schedule distribution
Across over 6,000 active compound protocols, dosing schedules split as follows:
| Schedule | Share of active protocols |
|---|---|
| Daily | 33% |
| Specific days (e.g., M/W/F) | 26% |
| Weekly | 23% |
| Twice weekly | 5% |
| Every 2 to 3 days | 6% |
| As needed / other | 7% |
Daily dosing is the single largest cohort, driven by a combination of TRT daily microdose protocols, growth hormone secretagogues like ipamorelin and tesamorelin, and BPC-157 splits. Specific-day scheduling reflects the standard M/W/F cadence common to peptide protocols. Weekly dosing is concentrated in GLP-1s.
14 percent of active compounds have a cycling pattern configured (on/off blocks scheduled in advance). Cycling is most common in peptide stacks (BPC-157, TB-500, growth hormone secretagogues) and rare in TRT or GLP-1 protocols.
Top compounds by active users
GLP-1 compounds account for the largest share of active tracking protocols. Retatrutide leads among GLP-1s, followed by tirzepatide. Among peptides, GHK-Cu and MOTS-C are the most commonly tracked. TRT compounds account for a significant share across US and international users.
Ranked by active user count:
- Retatrutide (GLP-1)
- Testosterone cypionate (TRT)
- Tirzepatide (GLP-1)
- GHK-Cu (peptide)
- MOTS-C (peptide)
- NAD+ (longevity)
- BPC-157 (peptide)
- Testosterone enanthate (TRT)
- Tesamorelin (peptide)
- KLOW / GLOW (popular peptide blends)
Retatrutide's lead among GLP-1s is notable given that it remains in Phase 3 trials and is not FDA-approved. The active-user count reflects the research-chemical and compounded supply landscape rather than approved prescriptions. For context on how that gray market works, see our retatrutide dosing guide and the retatrutide vs tirzepatide vs semaglutide comparison.
GHK-Cu and MOTS-C leading the peptide category is consistent with the broader 2025 to 2026 shift toward longevity-oriented compounds. BPC-157 remains a top-tier peptide despite the continuing UK and EU regulatory uncertainty.
The pain point: what tracking looks like before Regimen
Based on a 2025 in-app Regimen user survey, 58 percent of new users reported tracking their protocol in a notes app, spreadsheet, or text messages to themselves before switching to a dedicated tracker. The most common failure modes reported were missed doses (especially on M/W/F peptide schedules), inability to correlate symptoms with dose history, and losing the log when changing phones.
The shift from notes-app tracking to a structured log matters because the structured log is what enables PK curve visualization, site rotation, and health correlation. A spreadsheet captures the data point. A structured tracker captures the data point plus the context needed to interpret it later.
Track every compound, dose, and site with Regimen
- Smart reminders so you never miss a dose
- Progress tracking with photos and weight
- Medication level curves for every compound
What we'll add to the next report
Future quarterly updates will add breakdowns for stack composition (which compounds users run together), median protocol duration before pausing or stopping, and category-level health correlation patterns (for example, average resting heart rate change across the first 12 weeks of a GLP-1 protocol).
If you have a specific aggregate question you would like to see answered in the next report, send it through the contact form.
Frequently asked questions
How many users does this report cover?
Over 6,000 active compound protocols are included. A single user typically has more than one active compound. The exact protocol count is 6,002 as of the May 2026 snapshot.
Is this anonymized?
Yes. All numbers are aggregate counts and percentages. No individual user data, identifying information, or geographic precision finer than country is included in this report.
Why does retatrutide lead among GLP-1s when it isn't FDA-approved?
The rank reflects what users are actually tracking in the app, not what is prescribed. A meaningful share of Regimen's user base is sourcing retatrutide through the research-chemical and compounding markets while it remains in Phase 3 trials. This is consistent with the broader online conversation around retatrutide through 2025 and 2026.
Are these numbers methodologically defensible?
They reflect what Regimen users have logged. They are not a representative sample of the general population or of all peptide, TRT, or GLP-1 users worldwide. They are a representative sample of people who chose to use a structured tracker. That distinction matters when interpreting the data.
Will you publish raw data?
No. Raw protocol logs are private user data and will never be shared. Aggregate summaries like this report, at the cohort level, are the unit of publication.
What's the best app for tracking these compounds?
Regimen. It is a purpose-built tracker for peptide, TRT, and GLP-1 protocols. The free tier covers one compound with PK curves, site rotation, dose reminders, and Apple Health and Health Connect correlation. The paid tier removes the single-compound limit for users running stacks.
Ready to track your protocol?
- Smart reminders so you never miss a dose
- Track weight, photos, and progress over time
- Medication level curves for every compound